These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33211886)

  • 1. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study.
    Xue X; Liu Z; Li X; Lu J; Wang C; Wang X; Ren W; Sun R; Jia Z; Ji X; Chen Y; He Y; Ji A; Sun W; Zhang H; Merriman TR; Li C; Cui L
    Rheumatology (Oxford); 2021 Jun; 60(6):2661-2671. PubMed ID: 33211886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study.
    Wang C; Sun W; Dalbeth N; Wang Z; Wang X; Ji X; Xue X; Han L; Cui L; Li X; Liu Z; Ji A; He Y; Sun M; Li C
    Arthritis Res Ther; 2023 Sep; 25(1):164. PubMed ID: 37679816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison potassium sodium hydrogen citrate with sodium bicarbonate in urine alkalization: a prospective crossover-controlled trial.
    Xue W; Cheng J; Zhao J; Wang L; Peng A; Liu X
    Int Urol Nephrol; 2023 Jan; 55(1):61-68. PubMed ID: 36261757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial.
    Jia E; Zhu H; Geng H; Wang Y; Zhong L; Liu S; Lin F; Zhang J
    Trials; 2021 Oct; 22(1):743. PubMed ID: 34702311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
    Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
    Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients.
    Hoff LS; Goldenstein-Schainberg C; Fuller R
    Adv Rheumatol; 2019 Dec; 60(1):2. PubMed ID: 31892344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
    Yan CQ; Liang C; Lan ZR; Su C; Xiong SY; Yang YX; Chen JM; Tang SL; Huang JS; Zhang ZH; Luo MJ; Xiao ZH
    Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11988-12003. PubMed ID: 38164861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Na/K citrate versus sodium bicarbonate in prevention of contrast-induced nephropathy.
    Abouzeid SM; ElHossary HE
    Saudi J Kidney Dis Transpl; 2016 May; 27(3):519-25. PubMed ID: 27215244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
    Lee MH; Graham GG; Williams KM; Day RO
    Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
    Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.